Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Pharma Industry Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies41
  • 7D-3.9%
  • 3M1.3%
  • 1Y30.9%
  • YTD3.5%

Over the last 7 days, the Pharma industry has dropped 3.9%, driven by Chugai Pharmaceutical declining 2.5%. This takes the industry's 12 month performance to a gain of 31%. Looking forward, earnings are forecast to grow by 8.9% annually.

Industry Valuation and Performance

Has the Japanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 16 Apr 2026JP¥48.7tJP¥17.3tJP¥2.2t15.2x22.4x2.8x
Sat, 14 Mar 2026JP¥50.2tJP¥17.3tJP¥2.2t16x23x2.9x
Mon, 09 Feb 2026JP¥48.2tJP¥17.2tJP¥2.2t14.8x21.5x2.8x
Wed, 07 Jan 2026JP¥46.6tJP¥16.9tJP¥1.9t16.9x24.5x2.8x
Fri, 05 Dec 2025JP¥45.9tJP¥16.9tJP¥1.9t15.5x24.1x2.7x
Sun, 02 Nov 2025JP¥41.2tJP¥16.9tJP¥1.9t14.8x21.4x2.4x
Tue, 30 Sep 2025JP¥39.2tJP¥16.8tJP¥1.8t15.9x21.4x2.3x
Thu, 28 Aug 2025JP¥40.1tJP¥16.8tJP¥1.8t15.8x21.9x2.4x
Sat, 26 Jul 2025JP¥41.0tJP¥16.8tJP¥1.7t17x23.6x2.4x
Mon, 23 Jun 2025JP¥39.4tJP¥16.8tJP¥1.8t15.3x22.3x2.3x
Wed, 21 May 2025JP¥39.7tJP¥16.8tJP¥1.8t14.1x22.5x2.4x
Fri, 18 Apr 2025JP¥37.9tJP¥16.5tJP¥1.5t14.1x25.1x2.3x
Sun, 16 Mar 2025JP¥39.9tJP¥16.5tJP¥1.5t16x26.5x2.4x
Tue, 11 Feb 2025JP¥40.1tJP¥16.4tJP¥1.3t15.2x30.6x2.4x
Thu, 09 Jan 2025JP¥41.3tJP¥16.1tJP¥1.4t16.1x29.2x2.6x
Sat, 07 Dec 2024JP¥42.6tJP¥16.1tJP¥1.4t15.1x30.2x2.7x
Mon, 04 Nov 2024JP¥45.0tJP¥16.0tJP¥1.4t15.8x32.1x2.8x
Wed, 02 Oct 2024JP¥43.6tJP¥15.5tJP¥1.2t15.6x36.3x2.8x
Fri, 30 Aug 2024JP¥48.6tJP¥15.5tJP¥1.2t17.9x40.5x3.1x
Sun, 28 Jul 2024JP¥44.8tJP¥15.1tJP¥1.1t18.4x39.8x3x
Tue, 25 Jun 2024JP¥41.2tJP¥15.0tJP¥1.1t17.9x37.6x2.7x
Thu, 23 May 2024JP¥40.3tJP¥15.0tJP¥1.1t16.5x36.8x2.7x
Sat, 20 Apr 2024JP¥38.8tJP¥14.8tJP¥1.2t18.6x32.2x2.6x
Mon, 18 Mar 2024JP¥42.6tJP¥15.1tJP¥1.2t19.7x35.1x2.8x
Wed, 14 Feb 2024JP¥41.7tJP¥15.0tJP¥1.3t20.5x32.6x2.8x
Fri, 12 Jan 2024JP¥41.6tJP¥15.2tJP¥1.4t20.1x30.2x2.7x
Sun, 10 Dec 2023JP¥39.5tJP¥15.2tJP¥1.4t20.1x28.7x2.6x
Tue, 07 Nov 2023JP¥38.8tJP¥15.1tJP¥1.3t22.8x28.9x2.6x
Thu, 05 Oct 2023JP¥39.8tJP¥14.9tJP¥1.4t22.4x27.9x2.7x
Sat, 02 Sep 2023JP¥40.6tJP¥14.9tJP¥1.4t23.5x28.4x2.7x
Mon, 31 Jul 2023JP¥38.7tJP¥14.7tJP¥1.5t20.8x26.5x2.6x
Wed, 28 Jun 2023JP¥40.1tJP¥14.6tJP¥1.5t20.8x27.4x2.7x
Fri, 26 May 2023JP¥40.3tJP¥14.6tJP¥1.5t19.7x27.6x2.8x
Sun, 23 Apr 2023JP¥38.2tJP¥14.3tJP¥1.5t17.8x26x2.7x
Price to Earnings Ratio

26x


Total Market Cap: JP¥38.2tTotal Earnings: JP¥1.5tTotal Revenue: JP¥14.3tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Pharma Industry Price to Earnings3Y Average 28.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Japanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 22.4x which is lower than its 3-year average PE of 28.6x.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 14% per year over the last three years.
  • Revenues for these companies have grown 6.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare industry?

JP Market3.22%
Healthcare-2.27%
Pharma-3.91%
Pharma-3.91%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4506 Sumitomo PharmaJP¥2.19k2.9%
+JP¥24.6b		331.5%PE7.9x
4534 Mochida PharmaceuticalJP¥3.64k2.8%
+JP¥3.5b		22.7%PE20.1x
4565 Nxera PharmaJP¥1.05k3.0%
+JP¥2.7b		33.3%PS3.2x
4553 Towa PharmaceuticalJP¥4.34k0.8%
+JP¥1.7b		73.9%PE10x
4886 ASKA Pharmaceutical HoldingsLtdJP¥2.72k1.4%
+JP¥1.1b		18.9%PE15.8x

Latest News

4530
JP¥6,045.00
Hisamitsu Pharmaceutical
7D
0.05%
1Y
35.2%
4578
JP¥10,545.00
Otsuka Holdings
7D
-4.6%
1Y
55.7%

4578: Morgan Stanley Upgrade And Buybacks Will Shape Balanced Forward Expectations

Analysts have raised their price target for Otsuka Holdings from ¥10,850 to ¥11,650, citing updated expectations for revenue growth, profit margins, and future P/E that align with recent Street research, including the upgrade highlighted by Morgan Stanley. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target of ¥11,650 as more in line with updated expectations for revenue growth and profit margins that are reflected in recent Street work.
4507
JP¥3,299.00
Shionogi
7D
-8.5%
1Y
42.0%
4565
JP¥1,045.00
Nxera Pharma
7D
3.0%
1Y
33.3%
4502
JP¥5,654.00
Takeda Pharmaceutical
7D
-2.3%
1Y
34.9%

4502: Fair Outlook Will Depend On Late Stage Pipeline And Legal Outcomes

Analysts have adjusted their price target on Takeda Pharmaceutical from about ¥5,697 to roughly ¥6,004, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Takeda plans a leadership transition, with current CEO Christophe Weber set to retire at the 150th Ordinary General Meeting of Shareholders on June 24, 2026.
4151
JP¥2,521.50
Kyowa Kirin
7D
-4.1%
1Y
14.5%
4519
JP¥8,657.00
Chugai Pharmaceutical
7D
-2.5%
1Y
28.2%
4528
JP¥2,452.00
Ono Pharmaceutical
7D
-3.7%
1Y
42.9%
4547
JP¥4,815.00
Kissei Pharmaceutical
7D
0.3%
1Y
34.5%
4523
JP¥5,030.00
Eisai
7D
-2.4%
1Y
30.1%

4523: Alzheimer’s Franchise And Oncology Pipeline Will Support Steady Long Term Outlook

Analysts have trimmed their Eisai price target slightly to ¥5,009 from ¥5,012, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What's in the News Eisai and MSD submitted a Japan application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 LITESPARK-011 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and a safety profile consistent with each monotherapy (Product-Related Announcements).
4553
JP¥4,335.00
Towa Pharmaceutical
7D
0.8%
1Y
73.9%
4534
JP¥3,635.00
Mochida Pharmaceutical
7D
2.8%
1Y
22.7%
4579
JP¥880.00
RaQualia Pharma
7D
3.8%
1Y
163.5%
4506
JP¥2,192.00
Sumitomo Pharma
7D
2.9%
1Y
331.5%
4536
JP¥1,800.50
Santen Pharmaceutical
7D
-6.8%
1Y
29.1%
4886
JP¥2,722.00
ASKA Pharmaceutical HoldingsLtd
7D
1.4%
1Y
18.9%